Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. RCE's portfolio of antibiotic therapies seek to address health threats posed by drug resistant bacteria. Their lead candidate RECCE®327 is designed as abroad-spectrum antibiotic, formulated using synthetic polymer technology to treat bacterial sepsis (blood poisoning) and other bacterial infections, including superbugs.